Net Income (Loss) Attributable to Parent in USD of Arbutus Biopharma Corp from 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD and CAD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Arbutus Biopharma Corp quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2011 to Q3 2025.
  • Arbutus Biopharma Corp Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$7.74M, a 60.7% increase year-over-year.
  • Arbutus Biopharma Corp Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$42.3M, a 44.9% increase year-over-year.
  • Arbutus Biopharma Corp annual Net Income (Loss) Attributable to Parent for 2024 was -$69.9M, a 4.02% increase from 2023.
  • Arbutus Biopharma Corp annual Net Income (Loss) Attributable to Parent for 2023 was -$72.8M, a 4.89% decline from 2022.
  • Arbutus Biopharma Corp annual Net Income (Loss) Attributable to Parent for 2022 was -$69.5M, a 8.91% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Arbutus Biopharma Corp Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$42.3M -$7.74M +$12M +60.7% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 -$54.3M $2.52M +$22.3M 01 Apr 2025 30 Jun 2025 10-Q 13 Nov 2025
Q1 2025 -$76.6M -$24.5M -$6.65M -37.2% 01 Jan 2025 31 Mar 2025 10-Q 13 Nov 2025
Q4 2024 -$69.9M -$12.5M +$6.78M +35.1% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025
Q3 2024 -$76.7M -$19.7M +$387K +1.93% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 -$77.1M -$19.8M -$2.7M -15.8% 01 Apr 2024 30 Jun 2024 10-Q 13 Nov 2025
Q1 2024 -$74.4M -$17.9M -$1.54M -9.4% 01 Jan 2024 31 Mar 2024 10-Q 13 Nov 2025
Q4 2023 -$72.8M -$19.3M +$2.62M +11.9% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025
Q3 2023 -$75.5M -$20.1M -$2.54M -14.4% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$72.9M -$17.1M -$2.9M -20.4% 01 Apr 2023 30 Jun 2023 10-Q 06 Nov 2024
Q1 2023 -$70M -$16.3M -$574K -3.64% 01 Jan 2023 31 Mar 2023 10-Q 06 Nov 2024
Q4 2022 -$69.5M -$21.9M -$611K -2.87% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 -$68.8M -$17.6M +$1.59M +8.31% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023
Q2 2022 -$70.4M -$14.2M +$5.2M +26.8% 01 Apr 2022 30 Jun 2022 10-Q 07 Nov 2023
Q1 2022 -$75.6M -$15.8M +$616K +3.76% 01 Jan 2022 31 Mar 2022 10-Q 07 Nov 2023
Q4 2021 -$76.2M -$21.3M -$4.28M -25.1% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023
Q3 2021 -$72M -$19.2M -$403K -2.15% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 -$71.6M -$19.4M -$5.3M -37.6% 01 Apr 2021 30 Jun 2021 10-Q 09 Nov 2022
Q1 2021 -$66.3M -$16.4M -$2.52M -18.2% 01 Jan 2021 31 Mar 2021 10-Q 09 Nov 2022
Q4 2020 -$63.7M -$17M +$7.61M +30.9% 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2022
Q3 2020 -$71.4M -$18.8M +$63.7M +77.3% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 -$135M -$14.1M +$9.23M +39.6% 01 Apr 2020 30 Jun 2020 10-Q 04 Nov 2021
Q1 2020 -$144M -$13.9M +$9.39M +40.4% 01 Jan 2020 31 Mar 2020 10-Q 04 Nov 2021
Q4 2019 -$154M -$24.7M -$6.41M -35.1% 01 Oct 2019 31 Dec 2019 10-K 05 Mar 2020
Q3 2019 -$147M -$82.5M -$58M -237% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$89.3M -$23.3M -$26.4M -854% 01 Apr 2019 30 Jun 2019 10-Q 05 Nov 2020
Q1 2019 -$62.9M -$23.3M -$5.82M -33.4% 01 Jan 2019 31 Mar 2019 10-Q 05 Nov 2020
Q4 2018 -$57.1M -$18.2M +$17.7M +49.2% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020
Q3 2018 -$74.7M -$24.5M -$12.9M -111% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019
Q2 2018 -$61.9M $3.09M +$21.3M 01 Apr 2018 30 Jun 2018 10-K 05 Mar 2020
Q1 2018 -$83.2M -$17.4M +$1.2M +6.43% 01 Jan 2018 31 Mar 2018 10-K 05 Mar 2020
Q4 2017 -$84.4M -$35.9M +$183M +83.6% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019
Q3 2017 -$267M -$11.6M +$8M +40.8% 01 Jul 2017 30 Sep 2017 10-K 07 Mar 2019
Q2 2017 -$275M -$18.3M +$112M +86% 01 Apr 2017 30 Jun 2017 10-K 07 Mar 2019
Q1 2017 -$387M -$18.6M -$2.75M -17.3% 01 Jan 2017 31 Mar 2017 10-K 07 Mar 2019
Q4 2016 -$384M -$219M -$213M -4055% 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 -$171M -$19.6M +$9.39M +32.4% 01 Jul 2016 30 Sep 2016 10-K 16 Mar 2018
Q2 2016 -$180M -$130M -$115M -773% 01 Apr 2016 30 Jun 2016 10-K 16 Mar 2018
Q1 2016 -$65M -$15.9M -$3.89M -32.4% 01 Jan 2016 31 Mar 2016 10-K 16 Mar 2018
Q4 2015 -$61.1M -$5.26M +$904K +14.7% 01 Oct 2015 31 Dec 2015 10-K 22 Mar 2017
Q3 2015 -$62M -$29M -$20.4M -237% 01 Jul 2015 30 Sep 2015 10-K 22 Mar 2017
Q2 2015 -$41.6M -$14.9M -$8.81M -145% 01 Apr 2015 30 Jun 2015 10-K 22 Mar 2017
Q1 2015 -$32.8M -$12M +$6M +33.3% 01 Jan 2015 31 Mar 2015 10-K 22 Mar 2017
Q4 2014 -$38.8M -$6.17M -$3.57M -138% 01 Oct 2014 31 Dec 2014 10-K 09 Mar 2016
Q3 2014 -$35.3M -$8.6M -$2.7M -45.7% 01 Jul 2014 30 Sep 2014 10-K 09 Mar 2016
Q2 2014 -$32.6M -$6.08M -$3.07M -102% 01 Apr 2014 30 Jun 2014 10-K 09 Mar 2016
Q1 2014 -$29.5M -$18M -$15.4M -606% 01 Jan 2014 31 Mar 2014 10-K 09 Mar 2016
Q4 2013 -$14.1M -$2.6M 01 Oct 2013 31 Dec 2013 10-K 13 Mar 2015
Q3 2013 -$5.91M 01 Jul 2013 30 Sep 2013 10-K 13 Mar 2015
Q2 2013 -$3.02M 01 Apr 2013 30 Jun 2013 10-K 13 Mar 2015
Q1 2013 -$2.55M 01 Jan 2013 31 Mar 2013 10-K 13 Mar 2015

Arbutus Biopharma Corp Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$69.9M +$2.93M +4.02% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 -$72.8M -$3.39M -4.89% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 -$69.5M +$6.79M +8.91% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 -$76.2M -$12.5M -19.6% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023
2020 -$63.7M +$90M +58.5% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2022
2019 -$154M -$96.7M -169% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021
2018 -$57.1M +$27.4M +32.4% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020
2017 -$84.4M +$300M +78% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019
2016 -$384M -$321M -513% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018
2015 -$62.7M -$23.9M -61.5% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 -$38.8M -$24.8M -176% 01 Jan 2014 31 Dec 2014 10-K 22 Mar 2017
2013 -$14.1M -$43.7M -147% 01 Jan 2013 31 Dec 2013 10-K 09 Mar 2016
2012 $29.6M +$39.7M 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015
2011 -$10.1M 01 Jan 2011 31 Dec 2011 10-K 28 Mar 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.